Obesity

EMPOWER Trial (Exploratory Multi-arm Prevention Of WEight Regain)

ARD-201 will be an investigational, fixed-dose combination of ARD-101 and a DPP-4 inhibitor for the potential treatment of obesity and obesity-related conditions. It will be designed to be taken orally once a day. We believe combining ARD-101 with a DPP-4 inhibitor will support weight management and address unmet needs in obesity care.